AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

MarketsPricingSign inSign up free

OCRELIZUMAB

8 registrations across 7 African markets— 7 active

Markets with OCRELIZUMAB

🇬🇭Ghana
2 registrations
2 active
🇰🇪Kenya
1 registration
1 active
🇳🇬Nigeria
1 registration
1 active
🇹🇳Tunisia
1 registration
0 active
🇹🇿Tanzania
1 registration
1 active
🇿🇦South Africa
1 registration
1 active
🇿🇲Zambia
1 registration
1 active

Recent registrations

Brand / ProductMarketHolderStatusExpires
Ocrelizumab
Solution For Infusion
🇿🇲ZambiaRoche ProductsactiveDec 2029
Ocrevus
Concentrate For Solution For Infusion
🇰🇪KenyaF. Hoffmann- La Roche LtdactiveApr 2028
OCREVUS🇬🇭Ghana—activeMar 2027
OCREVUS🇬🇭Ghana—activeMar 2027
OCREVUS
Solution injectable pour perfusion / 300 mg
🇹🇳TunisiaRoche Pharma (Schweiz) AGexpiredJun 2020
OCREVUS🇿🇦South AfricaRoche Products (Pty) LtdactiveJan 1900
Ocrevus
Concentrate for solution for infusion
🇳🇬Nigeria—active—
OCREVUS
Solution for Injection and Infusion
🇹🇿TanzaniaF.Hoffmann-La Roche Limitedactive—

OCRELIZUMAB in Africa — Regulatory Overview

OCRELIZUMAB is registered across 7 African markets with 8 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Ghana, Kenya, Nigeria, Tunisia and 3 more. AfricaRegulatory refreshes this data daily from official government sources.

Of the 8 registrations, 7 (88%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.